Boehringer Sees Sales Rise
GLOBAL - The pharmaceutical company Boehringer Ingelheim saw sales rise by 8.3 per cent in the first six months of 2009 compared to the previous year and because of a positive exchange rate this translated into growth of 15.7 per cent.
28 July 2009
1 minute read
Net sales of €6,388 million compared with €5,522 million in the first six months of the previous year.
The operating income developed equally well over the previous year. Currency effects played their part here, too, adding to the positive development of the individual businesses.
Prof. Dr Dr Andreas Barner, Chairman of the Board of Managing Directors: "We have posted growth in our business areas Human Pharmaceuticals, thanks in particular to the success of our innovative prescription medicines, and in Animal Health, thanks to the growth in the segment of vaccines. Despite the negative impact in some areas as a result of the financial crisis, local business development in the first half of 2009 shows that Boehringer Ingelheim is maintaining its growth course, virtually unchanged, and continues to outpace the pharmaceutical market," said Andreas Barner.
Boehringer Ingelheim said it is expecting sales growth in the year as a whole to outpace the world pharmaceutical market.
The Animal Health business achieved growth of 27.9 per cent in local currency - 32.5 per cent when exchange reate to Euros are taken into consideration, with sales of €286 million.
The most significant growth driver was again the innovative pig vaccine INGELVAC CIRCOFLEX®.
TheCattleSite News Desk
